Avan Armaghani, MD, eagerly reports in the wake of ASCO 2022 on two crucial trials concerning treatment for metastatic breast cancer (mBC). The first, TROPiCS-02, investigated the extension of the antibody-drug conjugate sacituzumab govitecan to the treatment of hormone receptor–positive breast cancer. The second, DESTINY-Breast04, applied the antibody-drug conjugate trastuzumab deruxtecan to HER2-low mBC.
Both agents performed positively in terms of progression-free survival, with the latter especially producing a far-reaching clinical implication — specifically, the confirmation of HER2-low as a therapeutically targetable population of patients with mBC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: Cutting-Edge Performances by Antibody-Drug Conjugates in the Treatment of Breast Cancer - Medscape - Jun 14, 2022.